We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Gilead Sciences has become the 15th major drugmaker to limit its involvement with the 30-year-old 340B Drug Discount Program that was designed to serve low-income patient populations in the U.S. Read More
The FDA approved Evrysdi to treat patients two months and older with Type 1 spinal muscular atrophy in August 2020, making it the first oral drug approved to treat the disease. Read More
The FDA has approved the first generic version of AstraZeneca’s Symbicort, a blockbuster drug-device combination product for the treatment of asthma and chronic obstructive pulmonary disease (COPD). Read More
The FDA is asking its vaccines advisory committee to meet next month to make a recommendation on Pfizer’s and BioNTech’s March 15 request to amend its Emergency Use Authorization (EUA) for approval of a fourth shot/second booster of its COVID-19 vaccine Comirnaty for people age 65 and older. Read More
Patients treated with Aduhelm experienced decreased levels of tau — the second dysregulated protein in Alzheimer’s disease — which were associated with a slowing of cognitive decline, Biogen executive Samantha Budd Haeberlein said yesterday at the AD/PD 2022 meeting on Alzheimer’s disease and Parkinson’s disease in Barcelona, Spain, March 15-20. Read More